Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cost-Effectiveness of Subcutaneous Interferon Beta-1A in a Sub-Population of Multiple Sclerosis Patients (Kurtzke Expanded Disability Status Scale [EDSS]: >3.5-5.0).
MS Research Roundup: December 12, 2014
MS Research Roundup: January 22, 2015
Voxel Based Morphometry in Optical Coherence Tomography: Validation & Core Findings.
High-throughput platforms for the screening of new therapeutic targets for neurodegenerative diseases.
MAL Is a Regulator of the Recruitment of Myelin Protein PLP to Membrane Microdomains.
Comparing Characteristics of Hungarian "Real Life" Patients With Participants of RCTS: First-Line Disease Modifying Therapies in Multiple Sclerosis.
Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity.
Validation of White-Matter Lesion Change Detection Methods on a Novel Publicly Available MRI Image Database.
An Economic Evaluation of Subcutaneous and Intramuscular Interferon Beta-1a in Multiple Sclerosis Using a Direct Head-To-Head Study.
Short Term Reproducibility of a High Contrast 3-D Isotropic Optic Nerve Imaging Sequence in Healthy Controls.
The Impact of Adherence and Development of Neutralizing Antibodies to Interferons β on Treatment of Multiple Sclerosis in the Czech Republic.
Farming, Foreign Holidays, and Vitamin D in Orkney.
Minimally Invasive En Bloc Resection of Massive Obstructive Atrial Tumour.
MS Research Roundup: October 16, 2014
Persistence with Fingolimod Versus Dimethyl Fumarate in Patients with Multiple Sclerosis: Retrospective Analysis of us Open-Source Pharmacy Data.
A Multimodal Intervention for Patients with Secondary Progressive Multiple Sclerosis: Feasibility and Effect on Fatigue.
MS Drugs in Development: Firategrast, Ocrelizumab, and Ofatumumab
Long-term disability and prognostic factors in polyneuropathy associated with anti-myelin- associated glycoprotein (MAG) antibodies.
Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?
Is Poor Sleep Quality Associated With Greater Disability in Patients With Multiple Sclerosis?
Behavioral assessment of neuropathic pain, fatigue, and anxiety in experimental autoimmune encephalomyelitis (EAE) and attenuation by interleukin-10 gene therapy.
MS Research Roundup: April 18, 2014
Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients.
The effect of vitamin D-related interventions on multiple sclerosis relapses: a meta-analysis.
Pages
« first
‹ previous
…
34
35
36
37
38
39
40
41
42
…
next ›
last »